ArticleJournal for immunotherapy of cancer2025

Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events.

Sara Khattab et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.